Skip to main Content
Site Search

Advanced Search

  • Mondo Visione
  • Mondo Visione - Worldwide Exchange Intelligence
Member Login

Member Login

Forgotten your password?

Sequana Medical Lists On Euronext Brussels - Capital Raised Through IPO Will Enable The Execution Of Sequana Medical’s Strategy

Date 11/02/2019

Belgian-based medtech company Sequana Medical NV (ticker symbol: SEQUA) today began trading on Euronext Brussels (Compartment C) with an initial market capitalisation of approximately €107.2 million. This transaction demonstrates the attractiveness of Euronext as the leading stock exchange for European biotech and medtech companies. With this operation, Sequana Medical joins a large franchise of 89 life science companies (52 biotech and 37 medtech companies) currently listed on Euronext’s markets, representing a total market capitalisation of €22 billion per 31 January 2019.

Sequana Medical NV is a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders. Sequana Medical's first product is the alfapump®, a fully implantable, programmable, wirelessly-charged, battery-powered system. It has been approved in Europe for the treatment of liver refractory ascites and malignant ascites and has shown a strong performance in multiple clinical studies and over 650 implants. The alfapump® has recently been granted breakthrough device designation by the US FDA. The Company is also developing alfapump® DSR (Direct Sodium Removal), a novel and proprietary approach to the treatment of volume overload in heart failure for which a first-in-human study is ongoing.

Founded in Switzerland in 2006, Sequana has established its new corporate headquarters in Ghent, Belgium, in order to benefit from Belgium’s attractive healthcare ecosystem and ultimately to list on Euronext Brussels, one of the most dynamic stock exchanges in Europe for life sciences IPOs.

With an initial reference price set at €8.5 per share, Sequana Medical’s initial market capitalization stands at €107.2 million.

Ian Crosbie, Chief Executive Officer of Sequana Medical, said: "We are very pleased with the successful closing of our IPO on Euronext Brussels, which is renowned for being very supportive of high-quality listings in the healthcare space. The funds raised will support our commercial and clinical development with the goal to make the alfapump® and alfapump® DSR available to a broader patient group and address important unmet medical needs. We would like to thank all of our existing shareholders and our new investors for their support in making this transaction a success and we are looking forward to entering this exciting new phase for our Company."

To mark Sequana Medical’s first trading day, Ian Crosbie, Chief Executive Officer of Sequana Medical, rang the bell to open the markets in Brussels today.